MD. Hospital Vall d'Hebron. Hepatology. Gastroenterology. Viral hepatitis - towards elimination. Inmune liver diseases. Santander - Madrid - Barcelona
Barcelona
Joined October 2019
- Tweets82
- Following164
- Followers94
- Likes183
Juan Carlos Ruiz Cobo retweeted
🧵 HILO: Neuromoduladores en Gastroenterología
1️⃣ Los Trastornos de la Interacción Cerebro-Intestino (TICI) afectan el procesamiento central y periférico de estímulos en el eje cerebro-intestino. Incluyen dispepsia funcional, gastroparesia y SII. ¡Su tratamiento clave son los neuromoduladores! 🧠🦠 Todo lo que desees saber aqui sciencedirect.com/science/ar… @gastromx @motilidad @CidemoArgentina @ASENEM_ @aeg @drprapul @DraBarba @DeMadaria @coss_enriquemd @GastroMty @CMIMorg @pepebandera1 @velardemd @ConchaAlejandro @OPGEgastro @OxytocinLau
Juan Carlos Ruiz Cobo retweeted
#AEEH2025.
➡️'Hepatolotoxicidad por inhibidores de CDK4/6 en cáncer de mama metastático (CMM)', con @mar_riveiro (ganadora de una de las #Becas Gilead-AEEH).
✔️Un estudio multicéntrico que todavía está en marcha.
🗣️"El manejo del #DILI por CDKi es heterogéneo, y su
estandarización es una necesidad de futuro dada la reciente aprobación de #ribociclib y #abemaciclib en el contexto adyuvante, explica Mar. @LHuvh @CIBERehd #50CongresoAEEH
Juan Carlos Ruiz Cobo retweeted
🆕 @AmerGastroAssn Guidelines for Prevention & Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
▪️HBsAg (+)
▪️HBsAg (-), HBcAB (+)
🚨B-cell depleting agents
🚨Anthracycline
🚨Anti-TNF
🚨Anti-IL6
🚨Cytokine inh
🚨CAR-T
🚨TACE
🚨JAKi
🔗 gastrojournal.org/article/S0…
Juan Carlos Ruiz Cobo retweeted
🚨🚨Happy to share our last paper!!!🚨🚨
Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort - Journal of Hepatology journal-of-hepatology.eu/art…
Juan Carlos Ruiz Cobo retweeted
ACG Clinical Practice guideline on H. pylori was published in @AmJGastro today. Visual abstract gives a great summary. Thanks to my co authors! @ShailjaShahMD
Juan Carlos Ruiz Cobo retweeted
🗞️New article ▶️effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients @APandT @DigestivoHuvv @_ibima @JCRCobo @DrJLCalleja @Mariabutif 👇
onlinelibrary.wiley.com/doi/…
Juan Carlos Ruiz Cobo retweeted
Efficacy and safety of carvedilol in cirrhosis patients with uncomplicated ascites without high-risk esophageal varices, RCT
Carvedilol less
Complicated ascites
Refractory ascitis
Mortality
90% men
#EASLCongress #WeShareEASL
Juan Carlos Ruiz Cobo retweeted
Elena Vargas-Accarino presenting and discussing her poster on hepatitis C screening in primary care setting - EASL Congress 2024
Juan Carlos Ruiz Cobo retweeted
🆕Article in press❕
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial
#OpenAccess here👉journal-of-hepatology.eu/art…
#LiverTwitter
Juan Carlos Ruiz Cobo retweeted
PoCUS en lesión renal asociado a cirrosis en @AEcodigest por el Dr @Tubulocentric
Interesante charla👈
💡La ecografía aporta información en el paciente cirrotico, más allá del cribado, ascitis o Trombosis
♦️ Importante: evaluar la congestión del paciente cirrótico
#AEED2024
Juan Carlos Ruiz Cobo retweeted
🟪NEW Article in press❕
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with #cirrhosis: a systematic review and meta-analysis
🔓#OpenAccess at 👉jhep-reports.eu/article/S258…
#LiverTwitter
@EASLedu
@AASLDtweets
Happy to share results from Hepa-C registry! @AEEHLiver
SOF/VEL/VOX is an effective rescue therapy💊 for patients with #HCV 🦠infection who failed to first line therapies without differences between SOF/VEL or GLE/PIB prior treatment >>> 88.6% SVR
onlinelibrary.wiley.com/doi/…
Juan Carlos Ruiz Cobo retweeted
Fantastic collaboration with 🇪🇸 #POCUS experts! @Derasnef @EmiliSanAlv @JaimeMazonRuiz @Tubulocentric
Acute Kidney Injury and Point-of-Care Ultrasound in Liver Cirrhosis: Redefining Hepatorenal Syndrome
academic.oup.com/ckj/article…
Juan Carlos Ruiz Cobo retweeted
Adriana Palom from our Liver Unit @LHuvh presenting the influence of RNA-HDV on clinical events of #HDV patients at #AEEH2024
@VHIR_ @CIBERehd @AEEHLiver
Juan Carlos Ruiz Cobo retweeted
Read Open Access "An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury" by Riveiro-Barciela at bit.ly/42BlEzt
#livertwitter #immunotherapy
ALT A 2-step algorithm based on immunotherapy temporary discontinuation and liver biopsy allowed a corticosteroid-free management in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Juan Carlos Ruiz Cobo retweeted
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU - ScienceDirect sciencedirect.com/science/ar…
Juan Carlos Ruiz Cobo retweeted
No todo van a ser sesiones en bata😷, gran noche del talento joven digestivo del @vallhebron ✨🩺🚑 @LHuvh
@cherreradeguise @Albajmasip @alcala_glez_LG @sergio_g_mm @SerraXevi @elecesmar
Juan Carlos Ruiz Cobo retweeted
🆕Article in press❕
The adjusted prevalence of hepatitis delta virus (#HDV) in 25 countries and territories
🔓#OpenAccess at👉journal-of-hepatology.eu/art…
@PolarisObserv
#LiverTwitter
Juan Carlos Ruiz Cobo retweeted
Venga Barceloneses, este año es el primero que corremos en la ciudad!
Vamos a quedarnos por detrás de Madrid y Alicante??🏃🏃🏃
Apúntate ya! ⤵️
Todos los años los alicantinos tenemos un pique sano con Madrid, a ver quién tiene más inscritos en @Run4Pancreas
Madrid va ganando!
Ya seas de Alicante, Madrid o de cualquier parte, ayúdanos a financiar investigación contra el cáncer de páncreas en carreracancerpancreas.es
